Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Edwards Lifesciences Corp., profitability ratios (quarterly data)
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Edwards Lifesciences Corp. gross profit margin ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Edwards Lifesciences Corp. operating profit margin ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Edwards Lifesciences Corp. net profit margin ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Edwards Lifesciences Corp. ROE deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Edwards Lifesciences Corp. ROA deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Gross Profit Margin
Edwards Lifesciences Corp., gross profit margin calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Gross profit | 1,020,200) | 998,500) | 1,041,700) | 923,200) | 895,400) | 859,900) | 686,800) | 863,600) | 887,900) | 801,600) | 782,900) | 761,200) | 743,000) | 681,700) | 697,500) | 661,200) | 653,200) | 608,200) | 630,700) | 667,900) | ||||||
| Net sales | 1,329,700) | 1,310,200) | 1,376,000) | 1,216,600) | 1,191,700) | 1,140,900) | 925,000) | 1,128,700) | 1,174,100) | 1,094,000) | 1,086,900) | 993,000) | 977,700) | 906,600) | 943,700) | 894,800) | 888,500) | 821,500) | 841,800) | 883,500) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | 76.13% | 75.74% | 75.53% | 75.22% | 75.36% | 75.50% | 74.97% | 74.40% | 74.37% | 74.40% | 74.89% | 75.46% | 74.77% | 74.13% | 73.84% | 74.08% | 74.52% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 52.21% | 52.01% | 50.69% | 51.25% | 50.49% | 50.18% | 50.97% | 52.13% | 52.46% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 12.41% | 12.77% | 13.13% | 14.04% | 14.43% | 15.05% | 15.49% | 15.30% | 15.57% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 17.48% | 17.35% | 17.43% | 17.99% | 18.01% | 18.10% | 18.16% | 17.51% | 17.41% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | 60.95% | 60.44% | 59.24% | 57.60% | 55.98% | 55.04% | 55.28% | 55.85% | 55.74% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 17.09% | 17.30% | 17.57% | 19.38% | 19.71% | 20.18% | 20.43% | 18.70% | 18.77% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 69.32% | 69.12% | 68.69% | 66.48% | 65.65% | 66.44% | 67.07% | 69.04% | 69.45% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 65.19% | 63.85% | 64.57% | 65.76% | 67.41% | 68.96% | 69.22% | 69.62% | 70.04% | 70.33% | 70.40% | 70.25% | 69.77% | — | — | — | — | — | — | — | ||||||
| Shockwave Medical Inc. | 82.53% | 79.94% | 77.27% | 72.50% | 69.03% | 66.20% | 62.45% | 61.19% | 60.03% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 23.60% | 23.75% | 23.80% | 25.79% | 25.62% | 25.83% | 25.95% | 23.52% | 23.19% | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Gross profit margin = 100
× (Gross profitQ4 2021
+ Gross profitQ3 2021
+ Gross profitQ2 2021
+ Gross profitQ1 2021)
÷ (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
= 100 × (1,020,200 + 998,500 + 1,041,700 + 923,200)
÷ (1,329,700 + 1,310,200 + 1,376,000 + 1,216,600)
= 76.13%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Edwards Lifesciences Corp. gross profit margin ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Operating Profit Margin
Edwards Lifesciences Corp., operating profit margin calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Operating income (loss) | 374,400) | 390,300) | 542,100) | 383,500) | 351,400) | 357,800) | (169,700) | 358,100) | 310,800) | 294,300) | 267,500) | 274,200) | (5,300) | 248,900) | 252,100) | 252,500) | 342,200) | 214,000) | 241,000) | 298,300) | ||||||
| Net sales | 1,329,700) | 1,310,200) | 1,376,000) | 1,216,600) | 1,191,700) | 1,140,900) | 925,000) | 1,128,700) | 1,174,100) | 1,094,000) | 1,086,900) | 993,000) | 977,700) | 906,600) | 943,700) | 894,800) | 888,500) | 821,500) | 841,800) | 883,500) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | 32.30% | 32.73% | 33.19% | 20.63% | 20.46% | 19.62% | 18.36% | 27.45% | 26.38% | 20.01% | 19.81% | 20.15% | 20.10% | 30.15% | 29.89% | 30.46% | 31.89% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | 13.39% | 12.78% | 14.18% | 14.21% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 4.60% | 4.59% | 4.57% | 4.98% | 5.12% | 5.37% | 5.47% | 5.18% | 5.31% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 4.54% | 4.75% | 4.93% | 5.19% | 5.19% | 5.44% | 5.36% | 4.89% | 4.69% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | 25.35% | 24.63% | 25.04% | 22.30% | 18.99% | 17.61% | 17.37% | 18.01% | 18.25% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 5.15% | 4.91% | 3.68% | 4.83% | 4.97% | 5.59% | 6.99% | 5.47% | 5.49% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 3.80% | 3.40% | 4.97% | 6.60% | 6.56% | 7.77% | 6.77% | 5.09% | 4.96% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 31.89% | 32.55% | 31.27% | 26.01% | 24.09% | 23.95% | 25.86% | 30.52% | 30.69% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 14.89% | 11.44% | 12.77% | 14.25% | 16.57% | 20.67% | 20.47% | 21.25% | 20.51% | 20.48% | 20.22% | 21.70% | 22.20% | — | — | — | — | — | — | — | ||||||
| Shockwave Medical Inc. | -0.37% | -17.49% | -35.61% | -75.95% | -96.86% | -109.72% | -127.95% | -115.35% | -120.76% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 8.40% | 7.91% | 7.73% | 9.24% | 8.76% | 9.55% | 9.89% | 8.12% | 8.19% | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Operating profit margin = 100
× (Operating income (loss)Q4 2021
+ Operating income (loss)Q3 2021
+ Operating income (loss)Q2 2021
+ Operating income (loss)Q1 2021)
÷ (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
= 100 × (374,400 + 390,300 + 542,100 + 383,500)
÷ (1,329,700 + 1,310,200 + 1,376,000 + 1,216,600)
= 32.30%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Edwards Lifesciences Corp. operating profit margin ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Net Profit Margin
Edwards Lifesciences Corp., net profit margin calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income (loss) | 335,300) | 340,100) | 489,500) | 338,200) | 309,500) | 325,200) | (121,900) | 310,600) | 280,200) | 274,700) | 242,300) | 249,700) | 7,000) | 225,900) | 282,700) | 206,600) | (2,800) | 170,100) | 186,100) | 230,200) | ||||||
| Net sales | 1,329,700) | 1,310,200) | 1,376,000) | 1,216,600) | 1,191,700) | 1,140,900) | 925,000) | 1,128,700) | 1,174,100) | 1,094,000) | 1,086,900) | 993,000) | 977,700) | 906,600) | 943,700) | 894,800) | 888,500) | 821,500) | 841,800) | 883,500) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | 28.73% | 29.00% | 29.69% | 19.02% | 18.77% | 18.18% | 17.21% | 24.71% | 24.08% | 18.64% | 18.29% | 20.03% | 19.40% | 19.61% | 18.50% | 16.25% | 16.99% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | 10.50% | 9.89% | 11.15% | 11.56% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 3.11% | 4.97% | 4.93% | 5.22% | 5.31% | 3.40% | 3.43% | 3.22% | 3.35% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 2.72% | 2.67% | 2.60% | 2.74% | 2.68% | 3.00% | 3.14% | 2.77% | 2.59% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | 21.84% | 20.97% | 21.00% | 19.17% | 16.36% | 18.05% | 18.35% | 18.13% | 16.80% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 4.46% | 4.17% | 3.32% | 3.82% | 3.78% | 4.26% | 5.27% | 4.42% | 4.66% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 3.54% | 3.31% | 3.13% | 4.78% | 4.43% | 5.67% | 5.00% | 3.89% | 4.20% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 29.85% | 30.78% | 31.43% | 25.78% | 24.33% | 24.45% | 26.07% | 30.11% | 30.80% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 11.97% | 10.36% | 12.69% | 15.80% | 16.56% | 17.11% | 15.11% | 14.41% | 15.16% | 16.10% | 7.44% | 10.56% | 10.36% | — | — | — | — | — | — | — | ||||||
| Shockwave Medical Inc. | -3.85% | -21.60% | -40.60% | -83.47% | -96.92% | -108.73% | -126.34% | -112.25% | -119.06% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 6.06% | 5.56% | 5.37% | 6.46% | 6.03% | 6.66% | 6.94% | 5.63% | 5.76% | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Net profit margin = 100
× (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
= 100 × (335,300 + 340,100 + 489,500 + 338,200)
÷ (1,329,700 + 1,310,200 + 1,376,000 + 1,216,600)
= 28.73%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Edwards Lifesciences Corp. net profit margin ratio deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Return on Equity (ROE)
Edwards Lifesciences Corp., ROE calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income (loss) | 335,300) | 340,100) | 489,500) | 338,200) | 309,500) | 325,200) | (121,900) | 310,600) | 280,200) | 274,700) | 242,300) | 249,700) | 7,000) | 225,900) | 282,700) | 206,600) | (2,800) | 170,100) | 186,100) | 230,200) | ||||||
| Stockholders’ equity | 5,835,900) | 5,541,300) | 5,133,300) | 4,658,400) | 4,574,300) | 4,210,300) | 3,839,100) | 3,901,100) | 4,148,300) | 3,814,800) | 3,500,300) | 3,447,500) | 3,140,400) | 3,361,300) | 3,164,200) | 3,245,700) | 2,956,200) | 3,162,500) | 2,939,600) | 2,742,700) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | 25.76% | 26.66% | 28.49% | 18.27% | 18.00% | 18.86% | 19.37% | 28.40% | 25.24% | 20.28% | 20.71% | 22.20% | 23.00% | 21.19% | 20.75% | 17.25% | 19.74% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | 10.78% | 10.17% | 11.84% | 11.86% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 11.39% | 17.68% | 16.73% | 17.52% | 16.81% | 11.03% | 11.11% | 10.91% | 11.26% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 10.54% | 10.20% | 9.83% | 10.44% | 10.35% | 11.56% | 12.14% | 11.08% | 10.39% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | 14.24% | 13.54% | 13.12% | 11.76% | 9.17% | 9.70% | 9.56% | 10.53% | 9.94% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 16.93% | 15.44% | 12.10% | 13.92% | 13.77% | 14.61% | 17.17% | 15.08% | 15.15% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 18.24% | 16.44% | 16.72% | 26.23% | 24.53% | 26.34% | 24.29% | 21.16% | 22.49% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 14.32% | 14.80% | 14.97% | 11.56% | 10.90% | 11.38% | 13.00% | 16.30% | 16.69% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 7.01% | 5.70% | 7.05% | 8.77% | 9.44% | 10.26% | 9.23% | 8.78% | 9.25% | 9.87% | 4.56% | 6.30% | 6.12% | — | — | — | — | — | — | — | ||||||
| Shockwave Medical Inc. | -3.78% | -17.23% | -25.36% | -34.53% | -29.11% | -27.24% | -26.32% | -32.11% | -26.53% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 24.09% | 21.95% | 21.03% | 25.42% | 23.52% | 25.65% | 26.87% | 24.14% | 24.02% | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
ROE = 100
× (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ Stockholders’ equity
= 100 × (335,300 + 340,100 + 489,500 + 338,200)
÷ 5,835,900 = 25.76%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Edwards Lifesciences Corp. ROE deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Return on Assets (ROA)
Edwards Lifesciences Corp., ROA calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income (loss) | 335,300) | 340,100) | 489,500) | 338,200) | 309,500) | 325,200) | (121,900) | 310,600) | 280,200) | 274,700) | 242,300) | 249,700) | 7,000) | 225,900) | 282,700) | 206,600) | (2,800) | 170,100) | 186,100) | 230,200) | ||||||
| Total assets | 8,502,600) | 8,160,300) | 7,662,100) | 7,213,700) | 7,237,100) | 6,800,800) | 6,424,100) | 6,076,100) | 6,488,100) | 5,966,300) | 5,573,500) | 5,469,300) | 5,323,700) | 5,958,200) | 5,686,100) | 5,825,100) | 5,695,800) | 5,488,400) | 5,138,500) | 4,780,400) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | 17.68% | 18.10% | 19.09% | 11.80% | 11.38% | 11.68% | 11.58% | 18.23% | 16.14% | 12.97% | 13.01% | 13.99% | 13.57% | 11.96% | 11.55% | 9.61% | 10.25% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | 4.90% | 4.52% | 5.36% | 5.43% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cigna Group | 3.46% | 5.44% | 5.29% | 5.55% | 5.44% | 3.31% | 3.30% | 3.18% | 3.28% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| CVS Health Corp. | 3.39% | 3.23% | 3.12% | 3.22% | 3.11% | 3.41% | 3.51% | 3.13% | 2.98% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | 7.73% | 7.13% | 7.19% | 6.30% | 4.79% | 5.05% | 4.86% | 4.74% | 4.85% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 6.26% | 5.63% | 4.40% | 4.93% | 5.28% | 5.72% | 6.72% | 5.80% | 6.21% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Humana Inc. | 6.61% | 5.90% | 6.52% | 9.95% | 9.63% | 10.79% | 9.11% | 7.55% | 9.31% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 12.58% | 13.06% | 13.20% | 10.17% | 9.50% | 9.92% | 11.24% | 14.02% | 14.17% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 3.87% | 2.97% | 3.69% | 4.70% | 5.28% | 5.73% | 5.13% | 4.84% | 5.16% | 5.54% | 2.56% | 3.53% | 3.40% | — | — | — | — | — | — | — | ||||||
| Shockwave Medical Inc. | -2.64% | -12.69% | -19.12% | -26.21% | -24.15% | -23.01% | -22.48% | -25.86% | -22.04% | — | — | — | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 8.15% | 7.24% | 6.90% | 8.23% | 7.81% | 8.76% | 8.88% | 7.27% | 7.96% | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
ROA = 100
× (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ Total assets
= 100 × (335,300 + 340,100 + 489,500 + 338,200)
÷ 8,502,600 = 17.68%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Edwards Lifesciences Corp. ROA deteriorated from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |